Company news
Beijing Konruns Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Redemption of Cash Management Products Purchased with Certain Idle Raised Funds
November 3, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Report for Q3 2026
October 29, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Use of Idle Raised Funds for Cash Management
October 29, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Resolutions of the 8th Meeting of the 5th Board of Directors
October 29, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
October 29, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Reduction of Registered Capital and Notice to Creditors
October 29, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for KC1086 Combined with Fulvestrant for the Treatment of HR+HER2- Locally Advanced or Metastatic Breast Cancer
October 16, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
October 14, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 13, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Resolutions of the 7th Meeting of the 5th Board of Directors
October 13, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Repurchase and Cancellation of Restricted Shares Granted to Certain Incentive Participants but Not Yet Released from Trading Restrictions
October 13, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Change of Registered Capital and Amendment to the Articles of Association
October 13, 2026
(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares
October 9, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 29, 2026
Announcement on the Arbitration Result
September 24, 2026
Announcement on Results of the Initial Grant under the 2026 Restricted Share Incentive Plan
September 23, 2026
Announcement on Obtaining New Veterinary Drug Registration Certificate
September 15, 2026
Announcement on Release of Trading Restrictions and Listing of Shares for the 3rd Lock-up Period of the Initial Grant under the 2023 Restricted Share Incentive Plan
September 14, 2026
Announcement on Lifting of Restrictions and Listing of Shares for the Second Lock-up Period of Reserved Grant under the 2023 Restricted Share Incentive Plan
August 28, 2026
Semi-annual Report for 2026
August 25, 2026
Self-inspection Report on Trading in the Company's Shares by Insiders with Access to Inside Information in Relation to the 2026 Restricted Share Incentive Plan
August 6, 2026
Announcement on Progress in Repurchasing Shares
August 4, 2026
Announcement on Redemption of Cash Management Products Purchased with Certain Idle Raised Funds
July 31, 2026
Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Stock Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
July 14, 2026
Announcement on the Change in the Company's Registered Capital
July 3, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 30, 2026
Announcement on Achieving Conditions for Lifting Sales Restrictions in 3rd Lifting Period of Initially Granted Part and 2nd Lifting Period of Reserved Granted Part under the 2023 Restricted Stock Incentive Plan
June 23, 2026
Announcement on Adjusting Total Cash Dividends for 2025 Annual Profit Distribution
June 15, 2026
Announcement on Progress in Repurchasing 1% Shares through Call Auction and Repurchasing Shares
June 11, 2026
Announcement on Progress in Repurchasing Shares
June 1, 2026
Announcement on presentation of KC1036 for the treatment of advanced thymic tumors in the form of a poster at the 2026 ASCO Annual Meeting
May 28, 2026
Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management
May 15, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 14, 2026
Announcement on the Acceptance of the Marketing Authorization Application for Jincaopian Tablets
April 24, 2026
Announcement on Presentation of Preclinical Study Data of Innovative Drugs KC1086 and KC1101 at the AACR Annual Meeting 2026
April 23, 2026
Announcement on the Implementation of Directors’ and Senior Management Members’ Remuneration in 2025 and the Plan for 2026
April 22, 2026
Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
April 9, 2026
Announcement on Canceling Special Accounts for Partial Raised Funds and Special Settlement Accounts for Cash Management
March 23, 2026
Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma
March 18, 2026
Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors
March 4, 2026
Announcement on Using Partial Idle Raised Funds for Cash Management and Redemption
February 4, 2026
Earnings Preannouncement for 2025
January 7, 2026
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
January 4, 2026
Announcement on Election of Employee Director
December 30, 2025
Announcement on FDA Approval for Clinical Trials of KC1086 Project
December 24, 2025
Announcement on Company Re-certified as High-tech Enterprise
December 17, 2025
Announcement on Resolutions of the 18th Meeting of the 4th Board of Supervisors
December 15, 2025
Announcement on Implementing Repurchase and Cancellation under 2023 Restricted Stock Incentive Plan
December 3, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 26, 2025
Announcement on Result of Shareholding Reduction by Shareholder
November 3, 2025